Settlement with CVS Caremark could save people billions on prescriptions
The settlement follows allegations that the pharmacy benefit manager favored higher-priced insulin versions to boost rebates, driving up costs for a lifesaving drug.
A settlement with CVS Caremark could reduce prescription costs by billions for people nationwide. The agreement comes after allegations that the pharmacy benefit manager preferred more expensive versions of insulin to increase rebate payments, which raised prices for the lifesaving medication.